Head of Clinical Biomarker Technologies in Early Clinical Development, Pfizer
Dr. Marshall is the head of Clinical Biomarker Technologies in Early Clinical Development, Pfizer. His group is responsible for the development and validation of novel biomarkers in early clinical trials, spanning mass spec, flow cytometry, ligand binding and genetic biomarkers.